



#7
RECEIVED

JUN 26 2002

TECH CENTER 1600/2900

1

SEQUENCE LISTING

<110> MENRAD, ANDREAS
REDLITZ, ALEXANDER
KOPPLITZ, MARCUS
EGNER, URSULA
BAHR, INKE

<120> RECEPTOR OF THE EDB-FIBRONECTIN DOMAINS

<130> SCH-1832

<140> 09/942,117

<141> 2001-08-30

<150> DE 10045803.3

<151> 2000-09-07

<150> DE 10123133.4-41

<151> 2001-05-20

<160> 22

<170> PatentIn Ver. 2.1

<210> 1

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 1

Val	Asp	Ile	Thr	Asp	Ser	Ser	Ile	Gly	Leu	Arg	Trp	Thr	Pro	Leu
1					5				10					15

<210> 2

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 2

Gly	Tyr	Tyr	Thr	Val	Thr	Gly	Leu	Glu	Pro	Gly	Ile	Asp	Tyr	Asp
1					5				10					15

<210> 3

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 3

Thr Gly Leu Glu Pro Gly Ile Asp Tyr Asp Ile Ser Val Ile Thr
1 5 10 15

<210> 4

<211> 91

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 4

Glu Val Pro Gln Leu Thr Asp Leu Ser Phe Val Asp Ile Thr Asp Ser
1 5 10 15

Ser Ile Gly Leu Arg Trp Thr Pro Leu Asn Ser Ser Thr Ile Ile Gly
20 25 30

Tyr Arg Ile Thr Val Val Ala Ala Gly Glu Gly Ile Pro Ile Phe Glu
35 40 45

Asp Phe Val Asp Ser Ser Val Gly Tyr Tyr Thr Val Thr Gly Leu Glu
50 55 60

Pro Gly Ile Asp Tyr Asp Ile Ser Val Ile Thr Leu Ile Asn Gly Gly
65 70 75 80

Glu Ser Ala Pro Thr Thr Leu Thr Gln Gln Thr
85 90

<210> 5

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 5

Arg Gly Asp Ser
1

<210> 6

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 6

Asp	Thr	Ile	Ile	Phe	Glu	Val	Pro	Gln	Leu	Thr	Asp	Leu	Ser	Phe
1				5					10					15

<210> 7

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 7

Glu	Val	Pro	Gln	Leu	Thr	Asp	Leu	Ser	Phe	Val	Asp	Ile	Thr	Asp
1				5					10					15

<210> 8

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 8

Thr	Asp	Leu	Ser	Phe	Val	Asp	Ile	Thr	Asp	Ser	Ser	Ile	Gly	Leu
1				5					10					15

<210> 9

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 9

Ile	Thr	Asp	Ser	Ser	Ile	Gly	Leu	Arg	Trp	Thr	Pro	Leu
1				5					10			

<210> 10

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 10

Ser	Ser	Ile	Gly	Leu	Arg	Trp	Thr	Pro	Leu	Asn	Ser	Ser	Thr	Ile
1				5					10					15

<210> 11

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 11

Arg	Trp	Thr	Pro	Leu	Asn	Ser	Ser	Thr	Ile	Ile	Gly	Tyr	Arg	Ile
1				5					10					15

<210> 12

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 12

Asn	Ser	Ser	Thr	Ile	Ile	Gly	Tyr	Arg	Ile	Thr	Val	Val	Ala	Ala
1				5					10					15

<210> 13

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 13

Ile	Gly	Tyr	Arg	Ile	Thr	Val	Val	Ala	Ala	Gly	Glu	Gly	Ile	Pro
1				5					10					15

<210> 14

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 14

Thr	Val	Val	Ala	Ala	Gly	Glu	Gly	Ile	Pro	Ile	Phe	Glu	Asp	Phe
1				5					10					15

<210> 15

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 15

Gly	Glu	Gly	Ile	Pro	Ile	Phe	Glu	Asp	Phe	Val	Asp	Ser	Ser	Val
1				5					10					15

<210> 16

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 16

Ile	Phe	Glu	Asp	Phe	Val	Asp	Ser	Ser	Val	Gly	Tyr	Tyr	Thr	Val
1				5					10					15

<210> 17

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 17

Phe	Glu	Asp	Phe	Val	Asp	Ser	Ser	Val
1				5				

<210> 18

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 18

Val Asp Ser Ser Val Gly Tyr Tyr Thr Val Thr Gly Leu Glu Pro
1 5 10 15

<210> 19

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 19

Gly Ile Asp Tyr Asp Ile Ser Val Ile Thr Leu Ile Asn Gly Gly
1 5 10 15

<210> 20

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 20

Ile Ser Val Ile Thr Leu Ile Asn Gly Gly Glu Ser Ala Pro Thr
1 5 10 15

<210> 21

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 21

Leu Ile Asn Gly Gly Glu Ser Ala Pro Thr Thr Leu Thr Gln Gln
1 5 10 15

<210> 22

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 22

Glu	Ser	Ala	Pro	Thr	Thr	Leu	Thr	Gln	Gln	Thr	Ala	Val	Pro	Pro
1				5				10					15	